Abstract 603P
Background
Glioblastoma is a malignant brain tumour with a high recurrence rate following stanadard first-line treatment. While there are currently guidelines from NICE and EANO on the postoperative surveillance intervals for these patients, they were not evidence-based, and the quality of such recommendations remains untested. We therefore set out to provide an evidence-based recommendation on the optimal postoperative radiological surveillance schedule for glioblastoma patients after surgical treatment, tailored based on the extent of surgical resection and completion of adjuvant treatment.
Methods
This was a territory-wide, multicentre retrospective analysis of consecutive adult patients with IDH-wildtype glioblastoma treated with surgery and radiotherapy (RT) across seven neurosurgical units in Hong Kong between 2006-2020 (n=228). Data were extracted from the Hong Kong Glioblastoma Registry (HK-GBM Registry). Interval-censored Kaplan-Meier curves were constructed for the stratified groups based on the event-free survival of included patients, defined as time from the start date of RT to the occurrence of any event (tumour progression or death). A piecewise exponential model with different hazard functions in predefined time intervals was used to describe each curve. Accordingly, adopting a 15% event rate criterion, we generated the surveillance schedules.
Results
For a 15% event yield each scan (15% event rate criterion), we propose that glioblastoma patients treated with gross total resection be monitored with MRIs around every 9 weeks until 86 weeks after starting RT. Meanwhile, patients with residual tumour after surgery should be monitored more frequently at every 7 weeks until 75 weeks after RT initiation; and the interval should be further shortened to every 4 weeks for patients who were unable to complete the standard 6-weeks concurrent chemoradiotherapy.
Conclusions
Radiological surveillance is an important tool to detect postoperative tumour progression. The extent of surgical resection and completion of adjuvant treatment are major factors associated with glioblastoma progression and the frequency of radiological surveillance should therefore be guided by these two factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong Neuro-oncology Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract